Introduction
============

Cancer is a major public health problem worldwide.[@b1-cmar-10-2711] Although a decrease of overall cancer mortality has been observed in the last two decades,[@b2-cmar-10-2711] it still causes 22% of noncommunicable disease deaths,[@b3-cmar-10-2711] due to the complex pathogenesis and few target treatments. Numerous experimental studies have attempted to reveal the mechanisms of tumorigenesis to provide clues for prevention, early diagnosis and target treatment. Developments in biotechnology have gradually unveiled some of the mysteries of cancer, with the identification of abundant DNA biomarkers, transcripts, protein and epigenetics. Noncoding RNAs (ncRNAs), which are the largest component of human genome transcripts, especially long noncoding RNAs (lncRNAs), have been confirmed as participating in diverse cellular processes from normal development to cancer.[@b4-cmar-10-2711] Increasing evidence suggests that lncRNAs could be the key regulators interacting with other components such as proteins, RNAs and DNAs;[@b5-cmar-10-2711],[@b6-cmar-10-2711] while regulating lncRNAs have been shown to have aberrant expression in tumor tissues.[@b7-cmar-10-2711]--[@b9-cmar-10-2711] To date, overwhelming numbers of cancer-related lncRNAs have been reported in the database of the Cancer Genome Atlas (TCGA) project[@b10-cmar-10-2711],[@b11-cmar-10-2711] as well as the noncode database (<http://www.noncode.org>) and LNCipedia (<http://www.lncipedia.org>). Because of being involved in the onset and development of cancer, some key lncRNAs are expected to play a crucial role in cancer detection, diagnosis and therapy.

lncRNA PVT1, homologous to the mouse plasmacytoma variant translocation gene (Pvt1), lies in human chromosome 8q24.21 and has attracted widespread attention.[@b12-cmar-10-2711] Recent studies showed that PVT1 was dysregulated in some human tumors, such as gastric cancer, nonsmall-cell lung cancer, colorectal cancer, esophageal cancer, pancreatic cancer, and hepatocellular carcinoma.[@b10-cmar-10-2711],[@b13-cmar-10-2711],[@b14-cmar-10-2711] High PVT1 expression was further found to increase the risk of tumor progression and poor prognosis.[@b13-cmar-10-2711],[@b15-cmar-10-2711]--[@b17-cmar-10-2711] Furthermore, studies of its mechanism suggested that aberrant level of PVT1 was linked to proliferation, angiogenesis and metastasis in human malignancies.[@b18-cmar-10-2711],[@b19-cmar-10-2711] PVT1 might act as an effective biomarker for tumorous prognosis surveillance. Nevertheless, the association between PVT1 expression and cancer prognosis is still not clear. Moreover, no meta-analysis has investigated the common effect of PVT1 on prognosis of most cancers based on multisource data.

The present study aimed to analyze the pooled effect of PVT1 on cancer prognosis by meta-analysis and further explore possibly common target genes of PVT1 in most cancers.

Materials and methods
=====================

TCGA sequencing data
--------------------

High-throughput RNA sequencing (RNA-Seq) and clinical data of different cancers were downloaded from <https://portal.gdc.cancer.gov/projects/(TCGA> database). Because it did not show in RNA-Seq data of most cancers, PVT1 expression level was redownloaded from <https://xenabrowser.net/heatmap/(TCGA> database). All the expression data were transformed into the format of log~2~ (Illumina Hiseq Pancan normalized numbers+1) after deleting the samples with no PVT1 data or where PVT1 was detected in corresponding normal tissues. Only the samples with clinical and PVT1 expression data were further enrolled for prognosis analysis.

Literature search strategy
--------------------------

English or Chinese studies on the role of PVT1 in human cancer were searched in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases with the keywords PVT1 and cancer. The references of retrieved papers and conference reports were also searched to identify relevant studies. The last search date was May 8, 2017.

Selection criteria of reported research
---------------------------------------

The titles and abstracts of searched articles were checked by 4 authors (YC, CW, ZS, and DW) after duplicates were removed. Then, the full text of eligible articles was retrieved. Eligible articles should have the following criteria: 1) the expression of PVT1 was analyzed by prognosis of human cancer; 2) the expression of PVT1 was detected in cancer tissue or circulating blood by reverse transcription polymerase chain reaction (RT-PCR), fluorescence in-situ hybridization or RNA-Seq; 3) the high and low groups of PVT1 expression were divided by the mean/median or ROC curve; and 4) HRs for survival (overall survival \[OS\], recurrence-free survival \[RFS\], disease-free survival \[DFS\], and progression-free survival \[PFS\]) or ORs for metastasis (tumor-node-metastasis \[TNM\], lymphatic invasion \[LI\], lymph node metastasis \[LNM\], depth of invasion \[DOI\], distant metastasis \[DM\], and differentiation \[DIF\]) were provided or could be calculated from the available data. Furthermore, if more than 1 report from the same cohort was published, only the most recent publication was included. Consensus in searching and exclusion was resolved by discussion of 3 other investigators (XC, YZ, and DH) if needed.

Data extraction and quality assessment
--------------------------------------

Four authors (YY, SW, HJ, and GZ) extracted the following data by an extraction form: first author's name, published year, region of cohort, cancer type, sample size, and HRs/ORs (95% CI). The quality of studies was assessed by New-castle--Ottawa Scale (NOS) and the score ≥ 6 was considered as high quality.

Statistical methods
-------------------

Univariate logistic regression was applied to analyze the risk of high PVT1 expression on metastasis as well as the effect of smoking on PVT1 expression, whereas the PVT1 effects on OS of 32 types of cancer were assessed by the Cox proportional hazards model with TCGA data. In the meta-analysis, the heterogeneity among studies was tested by inconsistency (*I*^2^) and *Q* tests (chi-square test). The fixed effects model was used to estimate the pooled effect with no statistical heterogeneity found (*I*^2^\<50%, *P~Q~*\>0.05); otherwise, a random effects model was used. Publication bias was assessed by Begg's and Egger's tests, as trim and fill analysis was used to adjust the pooled effects, if necessary.[@b20-cmar-10-2711] In addition, Engauge Digitizer 4.1 was used to analyze HRs and 95% CIs, when they were not provided directly in some studies. The correlations between PVT1 and other genes were estimated by Pearson correlation analysis. All tests, being considered statistically significant with *P*\<0.05, were two sided and performed by STATA 14.0 and Review Manager 5.3 (Cochrane network).

Results
=======

The effect of PVT1 on prognosis of TCGA cancers
-----------------------------------------------

The 9,451 patients with 32 types of cancer were divided into high and low groups with the cutoff point being the median of the PVT1 level which was stably detected in tissues. As shown in [Table 1](#t1-cmar-10-2711){ref-type="table"}, high PVT1 expression tended to deteriorate the prognosis of most cancers. Furthermore, it significantly increased the risk of TNM progression of breast cancer, head and neck cancer, kidney clear cell carcinoma (KIRC), and kidney papillary cell carcinoma (KIRP), with ORs being 1.168 (*P*=0.022), 1.947 (*P*\<0.001), 1.593 (*P*\<0.001) and 1.841 (*P*\<0.001), and significantly decreased the OS time of adrenocortical cancer, KIRC, lower grade glioma, pancreatic cancer, prostate cancer, sarcoma, thyroid cancer, endometrioid cancer, and ocular melanomas (UVM) with the HRs being 1.953 (*P*=0.001), 1.508 (*P*\<0.001), 1.519 (*P*\<0.001), 1.292 (*P*=0.002), 2.010 (*P*=0.041), 1.235 (*P*=0.043), 1.741 (*P*=0.006), 2.329 (*P*=0.005), 1.471 (*P*\<0.001), and 3.718 (*P*\<0.001). Conversely, the OS time of stomach cancer was significantly increased with high PVT1 expression (HR=0.848, *P*=0.046). In addition, smoking significantly increased the expression of PVT1 in KIRP (OR=1.319, *P*=0.007) and lung adenocarcinoma (OR=1.205, *P*=0.034).

Published studies of PVT1 on tumorous prognosis
-----------------------------------------------

The literature search resulted in 22 published studies eligible for the meta-analysis ([Figure S1](#SD1-cmar-10-2711){ref-type="supplementary-material"}), 19 from China,[@b13-cmar-10-2711],[@b15-cmar-10-2711],[@b16-cmar-10-2711],[@b18-cmar-10-2711],[@b19-cmar-10-2711],[@b21-cmar-10-2711]--[@b34-cmar-10-2711] and 3 from Japan,[@b35-cmar-10-2711] USA,[@b17-cmar-10-2711] and Italy.[@b36-cmar-10-2711] These studies involved 2,376 patients and 11 types of cancers, whose PVT1 level was detected in tumor tissue and circulating blood by RT-PCR. The main characteristics of each study are summarized in [Table S1](#SD6-cmar-10-2711){ref-type="supplementary-material"}. In addition, the included studies had high quality, with NOS scores of more than 6 for each study (data not shown).

Pooled effect of PVT1 on tumorous prognosis
-------------------------------------------

### Pooled effect of PVT1 on progression

Seventeen cohorts from published studies and 20 from TCGA provided the ORs of PVT1 on TNM progression in 8,128 patients. Under the random effects model, the pooled effect (pooled OR=1.46, 95% CI: 1.29--1.65) showed that high PVT1 significantly increased the risk of TNM progression ([Table 2](#t2-cmar-10-2711){ref-type="table"}, [Figure S2](#SD2-cmar-10-2711){ref-type="supplementary-material"}). Moreover, high PVT1 expression also significantly promoted the development of LNM, DOI and DM with pooled ORs of 2.77 (95% CI: 1.65--4.66), 4.32 (95% CI: 1.99--9.36) and 1.35 (95% CI: 1.01--1.80) under the random effects model ([Table 2](#t2-cmar-10-2711){ref-type="table"}, [Figure S3A--C](#SD3-cmar-10-2711){ref-type="supplementary-material"}). Furthermore, the risks of poor differentiation (pooled OR=1.62, 95% CI: 1.21--2.18) and lymphatic invasion (pooled OR=1.48, 95% CI: 1.02--2.15) were significantly increased in patients with high PVT1 expression under the fixed effects model ([Table 2](#t2-cmar-10-2711){ref-type="table"}, [Figure S3D--E](#SD3-cmar-10-2711){ref-type="supplementary-material"}).

### Pooled effect of PVT1 on survival

Forty-eight cohorts, 16 from published studies and 32 from TCGA, showed data for OS by PVT1 level in 11,022 patients. The pooled effect (pooled HR=1.32, 95% CI: 1.22--1.43) indicated that high PVT1 expression significantly decreased the OS time under the random effects model ([Table 3](#t3-cmar-10-2711){ref-type="table"}, [Figure S4](#SD4-cmar-10-2711){ref-type="supplementary-material"}). Similar effects have been shown on DFS (pooled HR=1.77, 95% CI: 1.46--2.13) and PFS (pooled HR=1.71, 95% CI: 1.45--2.00) which were reported in more than 2 cohorts ([Table 3](#t3-cmar-10-2711){ref-type="table"}, [Figure S5](#SD5-cmar-10-2711){ref-type="supplementary-material"}).

### Pooled effect of smoking on PVT1 expression

In addition, the effects of smoking on PVT1 expression were also reported in 12 cohorts within 3,600 patients. [Figure 1](#f1-cmar-10-2711){ref-type="fig"} depicts that smoking significantly increased the level of PVT1 expression under the fixed effect model (pooled OR=1.09, 95% CI: 1.01--1.16).

Correlation of PVT1 and relative genes in TCGA cancers
------------------------------------------------------

Thirty-four relative genes of PVT1 in cancers were summarized by systematic review. Besides 6 co-expression genes in 8q24, 28 target genes of transcriptional regulation of PVT1 were identified by functional experiments in a variety of human cell lines.[@b30-cmar-10-2711]--[@b33-cmar-10-2711],[@b35-cmar-10-2711],[@b37-cmar-10-2711]--[@b50-cmar-10-2711] The correlations between them and PVT1 were assessed with the merging RNA-Seq data of 32 types of cancers in TCGA. The PVT1 level was positive relative to the expression of 30 genes except for miR-30a (*r*=0.0196, *P*=0.06384), whereas miR-1206, miR-146a and miR-195 could not be detected by RNA-Seq technique ([Table 4](#t4-cmar-10-2711){ref-type="table"}). However, the relative coefficient of miR-152 (*r*=0.0382, *P*=0.00031) and TSHR (*r*=0.0897, *P*\<0.00001) was \<0.1, which was considered as no correlation. Because of significant correlations between PVT1 and co-expression genes, the effects of PVT1 on OS time were further assessed by Cox proportional hazards model by controlling the expression of MYC, miR-1207, miR-1208, miR-1205, miR-1205 and miR-1204 in 9451 patients of 32 types of cancer; as shown in [Table 5](#t5-cmar-10-2711){ref-type="table"}, high PVT1 expression still decreased the OS time with the HR being 1.29 (95% CI: 1.25--1.32).

Sensitivity analysis
--------------------

Sensitivity analysis was conducted for the association between PVT1 expression and TNM as well as OS. Each diagnosis test was deleted in turn to examine the influence of the removed data on the overall OR/HR. High PVT1 expression still significantly increased the risk of TNM and OS throughout (data not shown).

Publication bias
----------------

Publication bias was checked for the effects of PVT1 expression on TNM and OS ([Figure 2](#f2-cmar-10-2711){ref-type="fig"}). Begg's test showed significant rank correlation in studies of PVT1 effect on TNM (*Z*=2.45, *Pr*\> \|z\|=0.015) and OS (*Z*=3.01, *Pr*\>\|z\|=0.003). Given this result, we performed Egger's test where evidence of significance publication bias was found for TNM (*r*=1.81, 95% CI: 0.98--2.64, *P*\<0.0001) and OS (*r*=1.85, 95% CI: 0.95--2.74, *P*\<0.0001). Consequently, we performed trim and fill analysis; the adjusted pooled-OR of TNM and pooled-HR of OS were 1.31 (95% CI: 1.16--1.49) and 1.15 (95% CI: 1.11--1.18) with *P*\<0.0001 for heterogeneity of both.

Discussion
==========

This study aimed to assess the effect of PVT1 expression on cancer prognosis. The pooled effect showed that high PVT1 expression significantly increased the risk of poor differentiation and cancer metastasis, and significantly decreased the survival time of patients. Furthermore, the expression of PVT1 was significantly correlated to that of genes playing important roles in tumorigenesis. PVT1 could act as an effective biomarker for tumorous prognosis surveillance.

lncRNAs have been shown to act as master regulators of gene expression and thus could play a critical role in various biological functions and disease processes including cancer. With the advances in the RNA-Seq technique and improvement of bioinformatics, a large number of tumor associated lncRNAs have recently been discovered through genomics studies. However, only a few lncRNAs have been fully explored to understand the role in cancers such as regulation of transcription, translation, protein modification and the formation of RNA--protein or protein--protein complexes. PVT1 has been identified as an oncogene and highly correlated with Myc which participates in oncogene activation through Akt/c-Myc signaling pathway.[@b12-cmar-10-2711],[@b13-cmar-10-2711],[@b51-cmar-10-2711],[@b52-cmar-10-2711] Further research into the mechanism found PVT1 could target genes such as LASP1, p15, p16, EZH2, TSHR, and FOXM1 to promote tumor cell proliferation, migration and invasive capability in some cancers.[@b25-cmar-10-2711],[@b28-cmar-10-2711],[@b34-cmar-10-2711],[@b48-cmar-10-2711] Moreover, PVT1 was confirmed to promote protein stability of MYC, RSPO1, NOP2 and increase the level of them.[@b52-cmar-10-2711]--[@b54-cmar-10-2711] High PVT1 expression was also linked to poor prognosis of some cancers with most patients from China ([Table S1](#SD6-cmar-10-2711){ref-type="supplementary-material"}). The relationship between PVT1 expression and cancer prognosis is still ambiguous and should be identified by more samples from other groups. For stable detection in 32 types of TCGA cancer, it was found that PVT1 tended to increase the risk of TNM progression and decrease the OS time in most of them.

To further explore the unbiased effect of PVT1 on cancer prognosis, we performed a meta-analysis with the cohorts from TCGA and other published studies. The adjusted pooled OR of 1.31 (95% CI: 1.16--1.49) and pooled HR of 1.15 (95% CI: 1.11--1.18) indicated that high PVT1 increased the risk of TNM progression and decreased the overall survival time. The effect of high PVT1 on depth of invasive, lymph node metastasis, distant metastasis as well as poor differentiation and lymphatic invasion also provided direct and epidemiological evidence of PVT1 participating in cancer metastasis. Furthermore, five co-expression genes and 24 identified target genes were significantly associated with PVT1 in all TCGA cancers; although the relative coefficients of them were too small to declare a high degree of correlation, which might be caused by heterogeneity of huge samples of data. Moreover, high PVT1 expression dependently decreased the OS time of patients by controlling the influence of co-expressed genes. In addition, it was shown that the expression of PVT1 could be upregulated by smoking to deteriorate the cancer prognosis.[@b55-cmar-10-2711]--[@b57-cmar-10-2711] This suggested that PVT1 expression was an effectively common biomarker for human tumorous prognosis surveillance.

Some meta-analyses focused on the association between lncRNAs such as BANCR,[@b58-cmar-10-2711] HOTTIP,[@b59-cmar-10-2711] CCAT2,[@b60-cmar-10-2711] and metastasis as well as prognosis of cancer; all based on lncRNAs detected by RT-PCR from the cohorts of published studies. To search for an applicably common biomarker for prognosis surveillance, we focused on the effect of PVT1 expression, detected by RT-PCR and RNA-Seq on metastasis and survival as well as the correlation of PVT1 and possible target genes in all common cancer. In the present study, a new way was provided to improve the traditional meta-analysis, by which useful information not published in the literature could be found through published databases to provide more comprehensive evidence. More importantly, the possible mechanism and the common effect of PVT1 on prognosis of all cancers was proved. Furthermore, we provide coefficient references for correlation analysis of gene expression with huge amounts of RNA-Seq data. To our best knowledge, this is the first improved meta-analysis of PVT1 effect on cancer prognosis with the data from the cohorts of TCGA and published studies.

Our study also contains some limitations. Since PVT1 was identified as a common biomarker for cancer prognosis surveillance, there was no reference value to distinguish poor prognosis patients with PVT1 expression detected by RT-PCR or RNA-Seq. Second, although 24 possible target genes were proved to be significantly related to PVT1 expression in most cancers by pooled analysis, the mechanism of their involvement in PVT1 deteriorating cancer prognosis was still clear. Therefore, studies are needed to explore the reference value of PVT1 expression detected by RT-PCR/RNA-Seq to distinguish poor prognosis as well as the role of PVT1 target genes in cancer prognosis.

Conclusion
==========

This improved meta-analysis is the first to demonstrate the effect and possible mechanism of PVT1 on cancer prognosis. The expression of PVT1 could be a biomarker for tumorous prognosis surveillance.

Supplementary materials
=======================

###### 

The flow chart of meta-analysis.

###### 

The pooled effect value of PVT1 on TNM.

**Abbreviations:** IV, inverse variance methods; SE, standard error; UVM, ocular melanoma; SKCM, melanoma; STAD, stomach cancer; TGCT, testicular cancer; THCA, thyroid cancer; READ, rectal cancer; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney clear cell carcinoma; KIRP, kidney papillary cell carcinoma; HNSC, head and neck cancer; ESCA, esophageal cancer; ACC, adrenocortical cancer; BLCA, bladder cancer; BRCA, breast cancer; CHOL, bile duct cancer; TCGA, the Cancer Genome Atlas database.

###### 

The pooled effect value of PVT1 on **(A)** LNM, **(B)** DOI, **(C)** DM, **(D)** DIF, and **(E)** LI.

**Abbreviations:** DIF, differentiation; DM, distant metastasis; DOI, depth of invasive; IV, inverse variance methods; LI, lymphatic invasion; LNM, lymph node metastasis; SE, standard error.

###### 

The pooled effect value of PVT1 on OS.

**Abbreviations:** IV, inverse variance methods; OS, overall survival; SE, standard error; ACC, adrenocortical cancer; BLCA, bladder cancer; BRCA, breast cancer; CESC, cervical cancer; CHOL, bile duct cancer; COAD, colon cancer; DLBC, large B-cell lymphoma; ESCA, esophageal cancer; GBM, glioblastoma; HNSC, head and neck cancer; KICH, kidney chromophobe; KIRC, kidney clear cell carcinoma; KIRP, kidney papillary cell carcinoma; LGG, lower grade glioma; LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian cancer; PAAD, pancreatic cancer; PCPG, pheochromocytoma & paraganglioma; PRAD, prostate cancer; READ, rectal cancer; SARC, sarcoma; SKCM, melanoma; STAD, stomach cancer; TGCT, testicular cancer; THCA, thyroid cancer; THYM, thymoma; UCEC, endometrioid cancer; UCS, uterine carcinosarcoma; UVM, ocular melanoma.

###### 

The pooled effect value of PVT1 on **(A)** DFS and **(B)** PFS.

**Abbreviations:** DFS, disease-free survival; IV, inverse variance methods; PFS, progression-free survival; SE, standard error.

###### 

Basic data for all included studies in the meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                               Year   Country   Cancer type       Case (high/low)     Metastasis               Prognosis              Smoking on PVT1 OR (95% CI)                                                                                                            
  ------------------------------------ ------ --------- ----------------- ------------------- ------------------------ ---------------------- ----------------------------- ------------------------ ------------------------ ----------------------- ------ ----------------------- ----------------------
  Yuan et al[@b77-cmar-10-2711]        2015   China     GC (tissue)       112 (55/56)         3.346 (1.498--7.475)     2.337 (1.086--5.030)   2.337 (1.086--5.030)          11.846 (4.858--28.884)   2.075 (0.183--23.573)    NR                      OS\    2.280 (1.054--4.930)\   NR
                                                                                                                                                                                                                                                      DFS    2.210 (1.111--4.395)    

  Cui et al[@b79-cmar-10-2711]         2015   China     NSCLC (tissue)    108 (53/55)         3.168 (1.588--8.243)     NR                     2.289 (1.054--4.972)          11.026 (4.505--26.983)   2.118 (0.186--24.073)    1.054 (0.461--2.408)    OS\    1.72 (1.14--3.25)\      Irrelevant data
                                                                                                                                                                                                                                                      DFS    1.98 (1.16--4.35)       

  Xu et al[@b83-cmar-10-2711]          2016   China     GC (tissue)       190 (96/94)         NR                       NR                     NR                            NR                       NR                       NR                      DFS\   1.75 (1.25--2.56)\      NR
                                                                                                                                                                                                                                                      DSS    1.64 (1.15--2.39)       

  Takahashi et al[@b64-cmar-10-2711]   2014   Japan     CRC (tissue)      164 (133/31)        3.462 (1.494--8.022)     2.119 (0.915--4.908)   2.968 (1.282--6.870)          NR                       0.750 (0.075--7.451)     1.281 (0.267--6.149)    DFS    2.532 (1.152--10.747)   NR

  Li et al[@b78-cmar-10-2711]          2016   China     CRC (tissue)      30 (15/15)          0.750 (0.169--3.327)     NR                     NR                            NR                       NR                       NR                      DFS    5.84 (0.42--81.19)      NR

  Zheng et al[@b76-cmar-10-2711]       2015   China     ESCA (tissue)     77 (39/38)          3.450 (1.346--8.841)     NR                     NR                            NR                       NR                       NR                      NR     NR                      NR

  Huang et al[@b70-cmar-10-2711]       2015   China     PAAD (tissue)     85 (67/18)          3.442 (1.170--10.127)    NR                     0.276 (0.088--0.863)          1.829 (0.614--5.444)     NR                       1.550 (0.275--8.738)    OS     3.013 (1.574--6.673)    NR

  Yang et al[@b61-cmar-10-2711]        2014   China     NSCLC (tissue)    82 (65/17)          7.000 (1.829--26.788)    NR                     9.911 (2.093--46.925)         NR                       NR                       NR                      OS     3.273 (2.184--6.937)    NR

  Huang et al[@b72-cmar-10-2711]       2016   China     SCLC (tissue)     120 (60/60)         NR                       NR                     9.000 (3.939--20.566)         NR                       11.455 (3.683--35.628)   NR                      OS     1.782 (1.078--2.945)    NR

  Martini et al[@b81-cmar-10-2711]     2016   Italy     EOC (tissue)      Training 73 (NR)\   NR\                      NR\                    NR\                           NR\                      NR\                      NR\                     OS\    2.10 (1.40--3.30)\      NR
                                                                          Testing 126 (NR)    NR                       NR                     NR                            NR                       NR                       NR                      PFS\   1.70 (1.30--2.20)\      
                                                                                                                                                                                                                                                      OS\    1.30 (1.10--1.60)\      
                                                                                                                                                                                                                                                      PFS    1.60 (1.30--1.90)       

  Kong et al[@b68-cmar-10-2711]        2015   China     GC (tissue)       80 (40/40)          3.857 (1.526--9.750)     1.833 (0.755--4.455)   NR                            6.152 (2.334--16.211)    1.111 (1.002--1.232)     2.333 (0.932--5.839)    OS\    2.092 (1.068--4.096)\   NR
                                                                                                                                                                                                                                                      DFS    2.216 (1.130--4.345)    

  Ding et al[@b71-cmar-10-2711]        2015   China     HCC (tissue)      58 (49/9)\          0.311 (0.048--2.2028)\   NR\                    NR\                           NR\                      NR\                      1.534 (0.367--6.412)\   NR\    NR\                     NR\
                                                                          214 (157/57)        1.417 (0.772--2.603)     NR                     NR                            NR                       NR                       1.739 (0.937--3.228)    RFS\   1.653 (1.019--2.681)\   NR
                                                                                                                                                                                                                                                      OS     1.01 (0.65--1.56)       

  Zhang et al[@b75-cmar-10-2711]       2016   China     CESC (tissue)     90 (45/45)          NR                       NR                     NR                            NR                       NR                       NR                      OS     1.60 (0.55--4.66)       NR

  Wu et al[@b62-cmar-10-2711]          2017   China     PAAD (tissue)     30 (15/15)          8.000 (1.5224--2.042)    NR                     Unuseful data                 NR                       NR                       Unuseful data           NR     NR                      NR

  Ren et al[@b65-cmar-10-2711]         2016   China     GC (serum)        28 (13/15)          2.222 (0.426--11.603)    NR                     8.250 (1.328--51.263)         1.212 (0.216--6.800)     1.083 (0.926--1.267)     0.938 (0.205--4.294)    NR     NR                      NR

  Wan et al[@b63-cmar-10-2711]         2016   China     NSCLC (tissue)    105 (56/49)         3.710 (1.584--8.694)     NR                     2.842 (1.286--6.282)          NR                       NR                       NR                      OS\    2.464 (1.214--4.999)\   0.518 (0.226--1.186)
                                                                                                                                                                                                                                                      PFS    3.39 (1.74--6.63)       

  Zhou et al[@b82-cmar-10-2711]        2016   China     OS^\*^ (tissue)   53 (29/24)          NR                       NR                     NR                            NR                       NR                       NR                      OS     1.23 (0.37--4.05)       NR

  Iden et al[@b73-cmar-10-2711]        2016   USA       CESC (tissue)     121 (63/58)         NR                       NR                     NR                            NR                       NR                       NR                      OS     2.03 (1.01--4.08)       NR

  Li et al[@b67-cmar-10-2711]          2017   China     ESCC (tissue)     104 (52/52)         4.429 (1.917--10.229)    NR                     NR                            NR                       NR                       3.167 (1.235--8.117)    OS\    2.75 (1.35--5.59)\      1.185 (0.528--2.662)
                                                                                                                                                                                                                                                      DFS    1.42 (0.71--2.87)       

  Liu et al[@b66-cmar-10-2711]         2016   China     CESC (tissue)     85 (67/18)          3.442 (1.170--10.127)    NR                     3.621 (1.158--11.323)         1.829 (0.614--5.444)     1.455 (0.402--5.260)     1.550 (0.275--8.738)    OS     3.013 (1.574--6.673)    NR

  Huang et al[@b69-cmar-10-2711]       2015   China     RC (tissue)       54 (39/15)          4.400 (1.183--16.367)    NR                     2.783 (0.675--11.477)         NR                       NR                       NR                      NR     NR                      NR

  Chen et al[@b80-cmar-10-2711]        2016   China     GC (serum)        187 (112/75)        1.175 (0.567--2.434)     0.838 (0.458--1.532)   1.587 (0.672--3.751)          NR                       2.112 (0.845--5.278)     0.982 (0.501--1.927)    OS\    1.455 (1.005--2.105)\   NR
                                                                                                                                                                                                                                                      DFS    1.435 (0.998--2.061)    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** LI, lymphatic invasion; LNM, lymph node metastasis; DOI, depth of invasive; DM, distant metastasis; DIF, differentiation; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; DSS, disease specific survival; RFS, recurrence free survival; NR, no report; GC, gastric cancer; NSCLC, non-small cell lung cancer; CRC, colorectal cancer; ESCA, esophageal carcinoma; PAAD, pancreatic cancer; SCLC, small-cell lung cancer; EOC, epithelial ovarian cancer; HCC, hepatocellular carcinoma; CESC, cervical cancer; OS^\*^, osteosarcoma; ESCC, esophageal squamous cell carcinoma; RC, renal carcinoma.
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![Pooled OR of smoking on PVT1 expression.\
**Abbreviations:** SE, standard error; IV, inverse variance methods; BLCA, bladder cancer; CESC, cervical cancer; ESCA, esophageal cancer; HNSC, head and neck cancer; KICH, kidney chromophobe; KIRC, kidney clear cell carcinoma; KIRP, kidney papillary cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic cancer; TCGA, the Cancer Genome Atlas database.](cmar-10-2711Fig1){#f1-cmar-10-2711}

![Funnel plots to evaluate the publication bias of PVT1 expression on **(A)** TNM and **(B)** OS.\
**Abbreviations:** OS, overall survival; SE, standard error.](cmar-10-2711Fig2){#f2-cmar-10-2711}

###### 

The effect of PVT1 on TNM and survival as well as smoking on PVT1 expression

  Cancer types   Cases (high/low)   TNM (\[III+IV\]/\[I+ II\])   Overall survival (high/low)   Smoking (yes/no)                                  
  -------------- ------------------ ---------------------------- ----------------------------- ------------------ ---------------------- ------- ----------------------
  ACC            79 (39/40)         0.050                        1.611 (1.000--2.595)          0.001              1.953 (1.293--2.949)   NR      NR
  BLCA           407 (203/204)      0.282                        1.103 (0.923--1.317)          0.258              1.079 (0.946--1.232)   0.736   0.972 (0.822--1.148)
  BRCA           1,095 (547/548)    0.022                        1.168 (1.023--1.333)          0.927              0.993 (0.850--1.160)   NR      NR
  CESC           302 (151/151)      NR                           NR                            0.395              1.106 (0.877--1.395)   0.372   1.112 (0.881--1.404)
  CHOL           36 (18/18)         0.050                        2.450 (0.999--6.012)          0.750              0.946 (0.672--1.331)   NR      NR
  COAD           283 (141/142)      NR                           NR                            0.343              1.157 (0.856--1.562)   NR      NR
  DLBC           48 (24/24)         NR                           NR                            0.869              1.057 (0.454--2.548)   NR      NR
  ESCA           184 (92/92)        0.670                        1.076 (0.770--1.504)          0.627              1.060 (0.839--1.338)   0.265   0.839 (0.617--1.142)
  GBM            153 (76/77)        NR                           NR                            0.274              1.118 (0.915--1.365)   NR      NR
  HNSC           520 (260/260)      \<0.001                      1.947 (1.464--2.590)          0.102              1.126 (0.976--1.299)   0.256   1.119 (0.922--1.359)
  KICH           66 (33/33)         0.058                        1.383 (0.989--1.934)          0.174              1.365 (0.871--2.139)   0.308   1.222 (0.831--1.798)
  KIRC           533 (266/267)      \<0.001                      1.593 (1.309--1.938)          \<0.001            1.508 (1.279--1.777)   0.806   0.952 (0.645--1.406)
  KIRP           290 (145/145)      \<0.001                      1.841 (1.450--2.338)          0.056              1.245 (0.994--1.560)   0.007   1.319 (1.078--1.614)
  LGG            515 (257/258)      NR                           NR                            \<0.001            1.519 (1.333--1.731)   NR      NR
  LIHC           371 (185/186)      0.790                        0.981 (0.854--1.128)          0.346              1.049 (0.949--1.160)   NR      NR
  LUAD           515 (257/258)      0.552                        1.060 (0.875--1.285)          0.346              0.941 (0.829--1.068)   0.034   1.205 (1.015--1.430)
  LUSC           501 (250/251)      0.975                        1.004 (0.795--1.267)          0.434              0.947 (0.826--1.086)   0.827   0.972 (0.757--1.249)
  MESO           87 (43/44)         0.696                        0.883 (0.471--1.652)          0.467              1.129 (0.814--1.568)   NR      NR
  OV             304 (152/152)      NR                           NR                            0.923              0.994 (0.884--1.118)   NR      NR
  PAAD           178 (89/89)        0.551                        0.839 (0.471--1.494)          0.002              1.292 (1.101--1.515)   0.582   1.071 (0.839--1.367)
  PCPG           179 (90/89)        NR                           NR                            0.960              0.981 (0.463--2.078)   NR      NR
  PRAD           497 (248/249)      NR                           NR                            0.041              2.010 (1.028--3.929)   NR      NR
  READ           93 (46/47)         0.206                        1.461 (0.812--2.628)          0.345              1.344 (0.728--2.480)   NR      NR
  SARC           259 (129/130)      NR                           NR                            0.043              1.235 (1.007--1.516)   NR      NR
  SKCM           469 (234/235)      0.562                        1.063 (0.866--1.304)          0.334              1.076 (0.927--1.250)   NR      NR
  STAD           415 (207/208)      0.123                        1.171 (0.958--1.433)          0.046              0.848 (0.721--0.997)   NR      NR
  TGCT           134 (67/67)        0.423                        1.190 (0.777--1.822)          0.597              1.237 (0.562--2.179)   NR      NR
  THCA           505 (252/253)      0.904                        1.012 (0.828--1.237)          0.006              1.741 (1.171--2.590)   NR      NR
  THYM           120 (60/60)        NR                           NR                            0.005              2.329 (1.286--4.217)   NR      NR
  UCEC           176 (88/88)        NR                           NR                            \<0.001            1.471 (1.310--1.652)   NR      NR
  UCS            57 (28/29)         NR                           NR                            0.077              1.276 (0.974--1.673)   NR      NR
  UVM            80 (40/40)         0.086                        1.604 (0.935--2.753)          \<0.001            3.718 (1.956--7.067)   NR      NR

**Abbreviations:** ACC, adrenocortical cancer; BLCA, bladder cancer; BRCA, breast cancer; CESC, cervical cancer; CHOL, bile duct cancer; COAD, colon cancer; DLBC, large B-cell lymphoma; ESCA, esophageal cancer; GBM, glioblastoma; HNSC, head and neck cancer; KICH, kidney chromophobe; KIRC, kidney clear cell carcinoma; KIRP, kidney papillary cell carcinoma; LGG, lower grade glioma; LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian cancer; NR, not reported; PAAD, pancreatic cancer; PCPG, pheochromocytoma & paraganglioma; PRAD, prostate cancer; READ, rectal cancer; SARC, sarcoma; SKCM, melanoma; STAD, stomach cancer; TGCT, testicular cancer; THCA, thyroid cancer; THYM, thymoma; UCEC, endometrioid cancer; UCS, uterine carcinosarcoma; UVM, ocular melanoma.

###### 

The effect of high PVT1 expression on metastasis

  Type of metastasis   Cohorts   Cases   *P* value of heterogeneity   Pooled OR   95% CI
  -------------------- --------- ------- ---------------------------- ----------- ------------
  TNM                  37        8,128   \<0.0001                     1.46        1.29--1.65
  LNM                  11        1,130   0.001                        2.77        1.65--4.66
  DOI                  6         498     0.007                        4.32        1.99--9.36
  DM                   8         884     0.008                        1.35        1.01--1.80
  DIF                  8         1,116   0.500                        1.62        1.21--2.18
  LI                   4         543     0.130                        1.48        1.02--2.15

**Abbreviations:** LNM, lymph node metastasis; DOI, depth of invasive; DM, distant metastasis; DIF, differentiation; LI, lymphatic invasion.

###### 

The effect of high PVT1 expression on prognosis

  Type of prognosis   Cohorts   Cases    *P* value of heterogeneity   Pooled OR   95% CI
  ------------------- --------- -------- ---------------------------- ----------- ------------
  OS                  48        11,022   \<0.0001                     1.32        1.22--1.43
  DFS                 8         975      0.750                        1.77        1.46--2.13
  PFS                 3         304      0.110                        1.71        1.45--2.00

**Abbreviations:** OS, overall survival; DFS, disease-free survival; PFS, progression-free survival.

###### 

The characteristic of identified genes and correlation with PVT1 in 8,927 patients of 32 cancers

  Gene name        Genes identified in systematic review   Correlation with PVT1                                   
  ---------------- --------------------------------------- -------------------------- ------------------- -------- ---------
  *MIR1204*        miRNA                                   Co-expression              NR                  0.2234   0.00000
  *MIR1205*        miRNA                                   Co-expression              NR                  0.2664   0.00000
  *MIR1206*        miRNA                                   Co-expression              NR                  --       --
  *MIR1208*        miRNA                                   Co-expression              NR                  0.1430   0.00000
  *MYC*            mRNA                                    Co-expression              NR                  0.1918   0.00000
  *MIR1207(-5p)*   miRNA                                   Co-expression and target   BRCA                0.1982   0.00000
  *BCL2*           mRNA                                    Target                     OS^\*^              0.1666   0.00000
  *CASP3*          mRNA                                    Target                     CRC                 0.1722   0.00000
  *CCND1*          mRNA                                    Target                     OS^\*^              0.1774   0.00000
  *CD151*          mRNA                                    Target                     GC                  0.1761   0.00000
  *CDKN1A(p21)*    mRNA                                    Target                     PAAD, NSCLC         0.1735   0.00000
  *CDKN2A(p16)*    mRNA                                    Target                     GC                  0.1766   0.00000
  *CDKN2B(p15)*    mRNA                                    Target                     NSCLC, GC           0.1661   0.00000
  *DDB2*           mRNA                                    Target                     NSCLC               0.1755   0.00000
  *EZH2*           mRNA                                    Target                     CESC, THCA, NSCLC   0.1799   0.00000
  *FASN*           mRNA                                    Target                     OS^\*^              0.1769   0.00000
  *FGF2*           mRNA                                    Target                     GC                  0.1384   0.00000
  *HIF1A(HIF1a)*   mRNA                                    Target                     GC                  0.1667   0.00000
  *LASP1*          mRNA                                    Target                     ESCC                0.1714   0.00000
  *LATS2*          mRNA                                    Target                     NSCLC               0.1700   0.00000
  *MIR146A*        miRNA                                   Target                     PRAD                --       --
  *MIR152*         miRNA                                   Target                     GC                  0.0382   0.00031
  *MIR186*         miRNA                                   Target                     GC                  0.1146   0.00000
  *MIR195*         miRNA                                   Target                     CESC, OS^\*^        --       --
  *MIR200B*        miRNA                                   Target                     CESC                0.1965   0.00000
  *MIR203A*        miRNA                                   Target                     ESCC                0.1381   0.00000
  *MIR30A*         miRNA                                   Target                     GC                  0.0196   0.06384
  *MIR424*         miRNA                                   Target                     CESC                0.1641   0.00000
  *SMAD3*          mRNA                                    Target                     CESC                0.1713   0.00000
  *SMAD4*          mRNA                                    Target                     CRC                 0.1673   0.00000
  *SNAI1*          mRNA                                    Target                     GC                  0.1752   0.00000
  *TIMP1*          mRNA                                    Target                     OV                  0.1800   0.00000
  *TP53(p53)*      mRNA                                    Target                     OV                  0.1759   0.00000
  *TSHR*           mRNA                                    Target                     THCA                0.0897   0.00000

**Abbreviations:** NR, not reported; BRCA, breast cancer; OS^\*^, osteosarcoma; CRC, colorectal cancer; GC, gastric cancer; PAAD, pancreatic cancer; NSCLC, nonsmall-cell lung cancer; CESC, cervical cancer; THCA, thyroid cancer; ESCC, esophageal squamous cell carcinoma; PRAD, prostate cancer; OV, ovarian cancer; CRC, colorectal cancer.

###### 

The effect of PVT1 and coexpression genes on OS time under Cox proportional hazards model

  Gene         Wald      *P* value   HR (95% CI)
  ------------ --------- ----------- ----------------------
  *MYC*        71.07     \<0.0001    1.077 (1.058--1.095)
  *miR-1207*   5.933     0.015       1.011 (1.002--1.019)
  *miR-1208*   3.985     0.046       1.011 (1.001--1.021)
  *miR-1205*   19.593    \<0.0001    1.017 (1.009--1.025)
  *miR-1204*   313.171   \<0.0001    0.847 (0.831--0.862)
  *PVT1*       263.402   \<0.0001    1.285 (1.247--1.324)

[^1]: These authors contributed equally to this work
